

Gilead Sciences, Inc.
Medical Affairs
HCV CITE program: Continuum from Identification To Elimination

Through Medical Affairs, Gilead supports the efforts of academic institutions, clinical investigators, and research networks to help inform the scientific community about the impact of hepatitis C on patients and the health care system. Specifically, Gilead intends to support investigators focused on addressing the challenges associated with HCV Elimination for individuals infected with hepatitis C (including pan-virologic testing).

Through the Medical Affairs Investigator Sponsored Research process, Gilead will evaluate support of programs which address the following objectives:

- HCV Elimination projects for high risk and high prevalence populations and geographies, including demonstration of clinical and economic value of such programs
- Evaluation of novel patient care models to facilitate the flow of HCV-positive patients to medical care following diagnosis

Proposals must demonstrate the following:

- Clear scientific objectives based on a scientific hypothesis
- Potential scalability and sustainability of program to other practice settings
- Plan to publish and present results in scientific forums and to other organizations

Key Dates & Program Specifics:

1 July 2016 – Submission window opens

30 September 2016 - Submission window closes

31 October 2016 – Award notification announcement

The program provides awards for proposals completed in up to 3 years. Awards shall be for research purposes only; requests for HCV screening costs alone or for study drug alone will not be considered. Submissions should be made at <http://www.gilead.com/research/investigator-sponsored>. Questions about the announcement or application process should be submitted to the same web address or your local medical scientist.

Gilead reserves the right to approve or disapprove any application. Applications are reviewed by an internal review committee. Award of a grant in any one cycle does not infer that a subsequent grant will be awarded without further application and approval.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.